Thus, ROR1 appears to be a nearly ideal target in the treatment of tumors that overexpress it, that include solid tumors like small cell carcinoma of the lung and intestinal tumors, and hematopoietic tumors such CLL, mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL) and AML [16, 26–29] The combination of a small molecule ROR1 inhibitor with venetoclax has shown synergistic effects in treating tumor cells, suggesting the potential of ROR1 inhibitors as part of combination therapies for cancer treatment [30]. The gene discussed is ROR1; the disease is neoplasm.